# NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma

> **NCT05024318** · PHASE2 · RECRUITING · sponsor: **Peter MacCallum Cancer Centre, Australia** · enrollment: 20 (estimated)

## Conditions studied

- Renal Cell Carcinoma, Clear Cell, Somatic

## Interventions

- **DRUG:** Pembrolizumab
- **RADIATION:** Stereotactic Ablative Radiotherapy
- **PROCEDURE:** Nephrectomy

## Key facts

- **NCT ID:** NCT05024318
- **Lead sponsor:** Peter MacCallum Cancer Centre, Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-08
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05024318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05024318, "NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05024318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*